$SPRB
SPRUCE BIOSCIENCES, INC.

2022 Q3 Form 10-Q Financial Statement

#000095017022016486 Filed on August 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.766M $2.822M $3.225M
YoY Change -0.97% 8.75% 4.03%
% of Gross Profit
Research & Development $8.791M $9.060M $8.508M
YoY Change 2.14% -0.65% 26.72%
% of Gross Profit
Depreciation & Amortization $23.00K $9.000K $21.00K
YoY Change 27.78% 80.0% 61.54%
% of Gross Profit
Operating Expenses $11.56M $11.88M $11.73M
YoY Change 1.38% 1.43% 19.52%
Operating Profit -$11.56M -$11.88M -$11.73M
YoY Change 1.38% 1.43% 19.52%
Interest Expense $110.0K $94.00K $87.00K
YoY Change 25.0% 17.5% -2.25%
% of Operating Profit
Other Income/Expense, Net $266.0K $104.0K $58.00K
YoY Change 548.78% 420.0% 205.26%
Pretax Income -$11.40M -$11.87M -$11.76M
YoY Change -0.4% 0.83% 18.93%
Income Tax
% Of Pretax Income
Net Earnings -$11.40M -$11.87M -$11.76M
YoY Change -0.4% 0.83% 18.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.48 -$0.51 -$0.50
Diluted Earnings Per Share -$0.48 -$505.3K -$500.7K
COMMON SHARES
Basic Shares Outstanding 23.56M 23.49M 23.49M
Diluted Shares Outstanding 23.56M 23.49M 23.49M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.40M $93.30M $91.35M
YoY Change -2.08% -14.58% -38.53%
Cash & Equivalents $21.65M $47.21M $23.34M
Short-Term Investments $68.75M $46.09M $68.01M
Other Short-Term Assets $2.786M $390.0K $325.0K
YoY Change 825.58% -81.83% 19.49%
Inventory
Prepaid Expenses $2.821M $3.423M
Receivables
Other Receivables
Total Short-Term Assets $93.19M $96.51M $95.10M
YoY Change -0.78% -13.35% -37.27%
LONG-TERM ASSETS
Property, Plant & Equipment $1.229M $127.0K $131.0K
YoY Change -21.17% -92.25% -92.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $5.805M $17.60M
YoY Change -100.0% -80.5%
Other Assets $667.0K $674.0K $678.0K
YoY Change 60.72% 0.15% 43.34%
Total Long-Term Assets $2.112M $8.009M $19.89M
YoY Change -94.87% -75.03% 727.11%
TOTAL ASSETS
Total Short-Term Assets $93.19M $96.51M $95.10M
Total Long-Term Assets $2.112M $8.009M $19.89M
Total Assets $95.30M $104.5M $115.0M
YoY Change -29.45% -27.14% -25.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.181M $1.445M $1.109M
YoY Change 2.49% 29.83% -56.78%
Accrued Expenses $8.604M $7.846M $7.455M
YoY Change 24.1% 33.73% 73.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.216M $811.0K $405.0K
YoY Change
Total Short-Term Liabilities $12.00M $10.10M $8.969M
YoY Change 32.45% 44.73% 30.92%
LONG-TERM LIABILITIES
Long-Term Debt $3.685M $4.077M $4.485M
YoY Change -24.29% -16.02% -7.39%
Other Long-Term Liabilities $139.0K $117.0K $95.00K
YoY Change 172.55% -92.24% 1087.5%
Total Long-Term Liabilities $3.824M $4.194M $4.580M
YoY Change -22.24% -13.61% -5.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.00M $10.10M $8.969M
Total Long-Term Liabilities $3.824M $4.194M $4.580M
Total Liabilities $16.82M $15.39M $14.75M
YoY Change 9.47% 15.38% 11.13%
SHAREHOLDERS EQUITY
Retained Earnings -$138.2M -$126.8M -$114.9M
YoY Change 47.18% 53.7% 62.45%
Common Stock $217.5M $216.7M $215.8M
YoY Change 1.79% 2.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $78.48M $89.12M $100.2M
YoY Change
Total Liabilities & Shareholders Equity $95.30M $104.5M $115.0M
YoY Change -29.45% -27.14% -25.33%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$11.40M -$11.87M -$11.76M
YoY Change -0.4% 0.83% 18.96%
Depreciation, Depletion And Amortization $23.00K $9.000K $21.00K
YoY Change 27.78% 80.0% 61.54%
Cash From Operating Activities -$8.578M -$9.541M -$11.83M
YoY Change 12.91% -1.55% 34.59%
INVESTING ACTIVITIES
Capital Expenditures -$2.000K -$6.000K $0.00
YoY Change -96.92% 200.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$16.89M $33.51M -$7.491M
YoY Change 37.66% -155.09%
Cash From Investing Activities -$16.89M $33.51M -$7.491M
YoY Change 36.95% -155.08% 39326.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change -100.0%
Cash From Financing Activities -90.00K -99.00K -88.00K
YoY Change -629.41% -155.31% -131.1%
NET CHANGE
Cash From Operating Activities -8.578M -9.541M -11.83M
Cash From Investing Activities -16.89M 33.51M -7.491M
Cash From Financing Activities -90.00K -99.00K -88.00K
Net Change In Cash -25.56M 23.87M -19.41M
YoY Change 28.35% -133.93% 127.68%
FREE CASH FLOW
Cash From Operating Activities -$8.578M -$9.541M -$11.83M
Capital Expenditures -$2.000K -$6.000K $0.00
Free Cash Flow -$8.576M -$9.535M -$11.83M
YoY Change 13.86% -1.59% 34.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17568000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15833000
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001683553
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23560250
CY2021Q4 us-gaap Assets
Assets
126486000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1445000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39594
dei Entity Registrant Name
EntityRegistrantName
Spruce Biosciences, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2154263
dei Entity Address Address Line1
EntityAddressAddressLine1
2001 Junipero Serra Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 640
dei Entity Address City Or Town
EntityAddressCityOrTown
Daly City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94014
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
655-4168
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SPRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47210000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42748000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
46085000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
46221000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2821000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2530000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
390000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
396000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
96506000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
91895000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
216000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
216000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1314000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1479000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
5805000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
32459000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
674000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
437000
CY2022Q2 us-gaap Assets
Assets
104515000
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2823000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9060000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9119000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
811000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q2 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6953000
CY2021Q4 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4613000
CY2022Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
893000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1435000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10102000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8871000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4077000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4878000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1098000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1293000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
117000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
73000
CY2022Q2 us-gaap Liabilities
Liabilities
15394000
CY2021Q4 us-gaap Liabilities
Liabilities
15115000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23560250
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23560250
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23491881
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23491881
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
216731000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
214685000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-845000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-184000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126768000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-103133000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89121000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111371000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104515000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
126486000
us-gaap Net Income Loss
NetIncomeLoss
-21661000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-152000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2822000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2595000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6048000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5698000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
11882000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
11714000
us-gaap Operating Expenses
OperatingExpenses
23616000
us-gaap Operating Expenses
OperatingExpenses
21531000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11882000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11714000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23616000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21531000
CY2022Q2 us-gaap Interest Expense
InterestExpense
94000
CY2021Q2 us-gaap Interest Expense
InterestExpense
80000
us-gaap Interest Expense
InterestExpense
181000
us-gaap Interest Expense
InterestExpense
169000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
104000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
162000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11774000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-661000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12024000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11803000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24296000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21690000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23493613
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23329756
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23492960
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23306708
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
100243000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000
CY2022Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
905000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-152000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89121000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
111371000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-40000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2046000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-661000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
89121000
sprb Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
-1186000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
892000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
140723000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1010000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11774000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
149427000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
143000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
96000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2130000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-29000
us-gaap Net Income Loss
NetIncomeLoss
-21661000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
130106000
us-gaap Profit Loss
ProfitLoss
-23635000
us-gaap Profit Loss
ProfitLoss
-21661000
us-gaap Share Based Compensation
ShareBasedCompensation
2046000
us-gaap Share Based Compensation
ShareBasedCompensation
2130000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
27000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
30000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-108000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
166000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
155000
sprb Increase Decrease In Prepaid Expenses And Other Current Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
285000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-209000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-582000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-112000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-31000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-131000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-34000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21367000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18481000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
12978000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
60828000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
39000000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
26016000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60850000
sprb Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
227000
sprb Payments Of Deferred Offering Costs
PaymentsOfDeferredOfferingCosts
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
143000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
38000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000
us-gaap Net Income Loss
NetIncomeLoss
-23600000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
21400000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126800000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
10000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4990000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4770000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-187000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
459000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4462000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-78872000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42964000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
157366000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47426000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78494000
us-gaap Interest Paid Net
InterestPaidNet
110000
us-gaap Interest Paid Net
InterestPaidNet
97000
sprb Tax Withholding Payments On Restricted Stock Units
TaxWithholdingPaymentsOnRestrictedStockUnits
-40000
sprb Tax Withholding Payments On Restricted Stock Units
TaxWithholdingPaymentsOnRestrictedStockUnits
0
sprb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
50000
sprb Deferred Offering Costs Included In Accounts Payable And Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
0
CY2022Q2 sprb Cash Cash Equivalents And Investments
CashCashEquivalentsAndInvestments
99100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses as well as related disclosure of contingent assets and liabilities. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, accrued research and development expenses, stock-based compensation and uncertain tax positions. The Company bases its estimates on its historical experience and on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</span></p>
CY2022Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
135000
CY2021Q4 sprb Cash And Cash Equivalents And Available For Sale Amortized Cost
CashAndCashEquivalentsAndAvailableForSaleAmortizedCost
116931000
CY2021Q4 sprb Cash And Cash Equivalents And Available For Sale Gross Unrealized Loss
CashAndCashEquivalentsAndAvailableForSaleGrossUnrealizedLoss
184000
CY2021Q4 sprb Cash And Cash Equivalents And Available For Sale Fair Value
CashAndCashEquivalentsAndAvailableForSaleFairValue
116747000
CY2021Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
135000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47210000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
78278000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
216000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
216000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47426000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78494000
CY2022Q2 us-gaap Depreciation
Depreciation
9000
CY2022Q2 sprb Cash And Cash Equivalents And Available For Sale Amortized Cost
CashAndCashEquivalentsAndAvailableForSaleAmortizedCost
97056000
CY2022Q2 sprb Cash And Cash Equivalents And Available For Sale Gross Unrealized Loss
CashAndCashEquivalentsAndAvailableForSaleGrossUnrealizedLoss
845000
CY2022Q2 sprb Cash And Cash Equivalents And Available For Sale Fair Value
CashAndCashEquivalentsAndAvailableForSaleFairValue
96210000
sprb Weighted Average Remaining Contractual Term Maturities Available For Sale
WeightedAverageRemainingContractualTermMaturitiesAvailableForSale
P8M
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Debt Securities Available For Sale Realized Gain Loss Excluding Other Than Temporary Impairment
DebtSecuritiesAvailableForSaleRealizedGainLossExcludingOtherThanTemporaryImpairment
0
sprb Cash Equivalents And Short Term Investments Due Term
CashEquivalentsAndShortTermInvestmentsDueTerm
P1Y
CY2022Q2 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
135000
CY2021Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
135000
CY2022Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4700000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
49000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
127000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
140000
us-gaap Depreciation
Depreciation
18000
CY2021Q2 us-gaap Depreciation
Depreciation
5000
us-gaap Depreciation
Depreciation
9000
CY2022Q2 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
6226000
CY2021Q4 sprb Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3837000
CY2022Q2 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
347000
CY2021Q4 sprb Accrued General And Administrative Expenses
AccruedGeneralAndAdministrativeExpenses
416000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
380000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
360000
CY2022Q2 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
6953000
CY2021Q4 sprb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
4613000
CY2020Q1 sprb Operating Lease Commencement Month And Year
OperatingLeaseCommencementMonthAndYear
2020-09
CY2020Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P63M
CY2020Q1 sprb Lease Gross Commitment Amount
LeaseGrossCommitmentAmount
2300000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease includes an option to renew the lease term for an additional period of 60 months. The renewal option is not included in the lease term as the Company is not reasonably certain to exercise the option.
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2022Q2 sprb Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
100000
sprb Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
200000
CY2021Q2 sprb Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
100000
sprb Cash Paid For Amounts Included In Measurement Of Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilities
100000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5000000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
112000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
4888000
CY2022Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
811000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4077000
sprb Aggregate License Agreement Amount
AggregateLicenseAgreementAmount
23000000.0
sprb Additional Aggregate License Agreement Amount
AdditionalAggregateLicenseAgreementAmount
0
us-gaap Legal Fees
LegalFees
0
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one vote
us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7838681
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5745648
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
No further grants will be made under the 2016 Plan; however, shares subject to awards granted under the 2016 Plan will continue to be governed by the 2016 Plan.
CY2022Q2 sprb Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercised Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExercisedShares
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.56
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
905000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1010000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2046000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2130000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-11872000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-11774000
us-gaap Net Income Loss
NetIncomeLoss
-23635000
us-gaap Net Income Loss
NetIncomeLoss
-21661000
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23493613
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23329756
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23492960
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23306708
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4519198
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2645218

Files In Submission

Name View Source Status
0000950170-22-016486-index-headers.html Edgar Link pending
0000950170-22-016486-index.html Edgar Link pending
0000950170-22-016486.txt Edgar Link pending
0000950170-22-016486-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sprb-20220630.htm Edgar Link pending
sprb-20220630.xsd Edgar Link pending
sprb-ex31_1.htm Edgar Link pending
sprb-ex31_2.htm Edgar Link pending
sprb-ex32_1.htm Edgar Link pending
sprb-ex32_2.htm Edgar Link pending
sprb-20220630_lab.xml Edgar Link unprocessable
sprb-20220630_def.xml Edgar Link unprocessable
sprb-20220630_pre.xml Edgar Link unprocessable
sprb-20220630_cal.xml Edgar Link unprocessable
sprb-20220630_htm.xml Edgar Link completed